Aravax
PrivateLast Round
Series B
Jan 23, 2024
Total Funding Raised
$48.06M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Aravax operates in Healthcare & Life Sciences and is based in Melbourne. Its latest recorded funding round was a Series B round in January 2024.
Aravax is a biotechnology company developing next-generation immunotherapies for food allergies, with a lead product candidate, PVX108, for the treatment of peanut allergy.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Aravax Comparables
Compare Aravax with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Prota Therapeutics | 85% | |
| IgGenix | 84% | |
| Ukko | 83% |
For institutional investors. Book with your work email.
Aravax Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jan 23, 2024 | ||||
| Series A | May 29, 2018 | ||||
| Seed | Nov 23, 2015 |
For institutional investors. Book with your work email.
Aravax Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| UniSuper Management | Series B |
| Agati Capital | Series B |
| Victorian Government | Series B |
| Uniseed | Series B |
| Tenmile | Series B |
| Brandon Capital | Series A, Series B |
| Breakthrough Victoria | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors increased 273% MoM, reaching 790.
- Jul 16, 2026
Grew 18% QoQ, from 17 to 20 employees.
For institutional investors. Book with your work email.
Aravax Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Aravax's valuation, stock price, and market status.
Is Aravax a public or private company?
Aravax is a private company.
What is the current stock price of Aravax?
Aravax is a private company, so its shares have no public market price. Caplight tracks Aravax's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Aravax worth (valuation)?
Valuation information for Aravax is not publicly available.
Can I buy Aravax stock?
Aravax shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Aravax's last funding round?
Aravax's most recent funding round was Series B on January 23, 2024.
Who are the main investors in Aravax?
Key investors in Aravax include Tenmile, Brandon Capital.
Will Aravax IPO soon?
No public IPO plans have been announced for Aravax.
How can I track Aravax secondary market activity?
Caplight tracks bids, offers, and trades in Aravax's shares on secondary markets.